H. Lundbeck A — Earnings Release 2014

Feb 5, 2015

Valby, Copenhagen, 2015-02-05 07:54 CET (GLOBE NEWSWIRE) --

HIGHLIGHTS

-- In 2014 core products like Abilify Maintena®, Brintellix®, Northera(TM) and
Selincro® have been introduced in 39 markets worldwide and the ambitious
launch program will accelerate in 2015
-- Revenue from New Products increased 46% in local currency in 2014 and now
constitutes 33% of total revenue
-- US revenue reached DKK 3,758 million, an increase of 43% in local currency,
and constitutes 28% of Lundbeck’s revenue in 2014
-- Revenue in International Markets up 9% in local currency, largely driven by
China, and constitutes more than 31% of Lundbeck’s revenue
-- Brintellix has in its first year achieved a branded market share of more
than 14% in the US and in-market sales of approximately DKK 840 million.
Brintellix was launched in eleven additional countries in 2014
-- Abilify Maintena is off to a good start in Canada and in Europe. In the US,
Abilify Maintena seems to regain positive momentum. Additionally, the
QUALIFY study has provided superiority data on quality-of-life
-- Selincro was recently launched in France, a key market, and has been very
well received by physicians and patients
-- Brintellix has entered a pivotal program for treatment of adult patients
with ADHD
-- Brexpiprazole data presented at ACNP support the regulatory package in two
indications, schizophrenia and adjunctive therapy of major depression,
submitted in the US
-- Based on the financial results, the Board of Directors proposes no dividend
payout for 2014
-- Financial guidance for 2015 in constant exchange rates is DKK 13.2-13.7
billion in core revenue and around DKK 0 in core EBIT

In connection with the full year report, Lundbeck’s Chairman Håkan Björklund
said:

“We are moving through a challenging period of patent expirations to a period
of product launches. 2014 has been a successful year for Lundbeck with 39
launches across the world. We will continue to launch new products and in 2015
we potentially have more than 50 launches scheduled. We stay the course and in
2015 I also look forward to making brexpiprazole available in the US”.

DKK million FY 2014 FY 2013 Growth

Core Revenue 13,468 14,242 (5%)
Core EBIT 1,228 2,282 (46%)
Core EPS* 3.21 8.02
Core EBIT margin 9.1% 16.0%
Reported Revenue 13,468 15,258 (12%)
Reported EBIT 99 1,599 (94%)
Reported EPS (0.78) 4.36
Reported EBIT margin 0.7% 10.5%

*For definition of the measures “Core Revenue”, “Core EBIT” and “Core EPS”, see
page 14, and reconciliation to reported figures, see page 21-22